DiscoveryBioMed, Inc. is developing a novel and unprecedented “dual action” small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases

DiscoveryBioMed, Inc. (DBM, Inc.), fueled by recent advances in its Respiratory Diseases R&D program, has discovered and is developing a novel class of small molecule monotherapy that affects both major drug targets in CF. Proper function of the two target proteins that serve as channels for ions (conduits or transporters) for salt and water across the ciliated membrane that lines the airways, the cystic fibrosis transmembrane conductance regulator or CFTR (the protein product of the CF gene, a chloride ion channel) and ENaC (the epithelial sodium ion channel), becomes very abnormal in this devastating disease of children and young adults. “Our single drug corrects and activates mutant CFTR under basal conditions that is lost in CF, and, by virtue of that effect, also inhibits the function of ENaC that is too active in CF. The loss or deficit of CFTR and over-activity or surplus of ENaC in CF literally drains the salt and water from the airway surface. Cilia cannot beat on the dehydrated airway surface and mucus becomes sticky and infected,” explained Dr. Erik...

Read More

DiscoveryBioMed, Inc. is awarded a new Phase 2 SBIR grant award to develop new medicines to fight the diabetes and obesity epidemic in the US and globally

DiscoveryBioMed, Inc. (DBM, Inc.) has learned in recent days that it has been awarded a $1.61M Phase 2 Small Business Innovation Research (SBIR) grant award from the National Institutes of Health and its National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) to develop novel ‘first in class’ small molecule drugs to fight multiple disease abnormalities caused by high blood sugar (hyperglycemia) and high blood fat such as metabolic syndrome, type 2 diabetes mellitus and obesity. DBM’s Drs. John Streiff and Deborah Mai will lead these scientific studies for the company as dual principal investigators. Dr. Streiff will oversee chemistry efforts at optimizing key chemical series and Dr. Mai will lead the biological profiling efforts in primary human fat cells (called adipocytes) from normal and diseased donors. Early experiments that laid the groundwork for this continuing study were performed by Dr. Eric Seales, a former principal with DBM, Inc. “The small molecule drugs that we seek to develop up-regulate the endogenous production and secretion of adiponectin from human adipose cells and tissue. We are interested...

Read More

DiscoveryBioMed, Inc. promotes Dr. Deborah Mai to Chief Biological Officer

DiscoveryBioMed, Inc. (DBM, Inc.) is pleased to announce that Dr. Deborah Mai has been promoted to Chief Biological Officer, effective January 2015. Dr. Mai is responsible for and will direct the biological or bioassay initiatives for DBM. “Deborah has been a whirlwind since joining DBM first as an intern and then as a Staff Scientist in late 2011 and early 2012” explained Dr. Erik Schwiebert, DBM’s CEO and Chief Scientific Officer. "She conceived of, optimized and implemented her own drug discovery program during her Ph.D. dissertation at the University of Alabama at Birmingham and then sought to continue those efforts in the biotechnology space. As such, she was a perfect fit to join the DBM team." Dr. Mai has been a creative and innovative force in the programs that she has developed or improved at DBM. She has embraced the use of human cell platforms in Drug Discovery and Development and has seen repeatedly the ‘value add’ of using primary normal and diseased human cells in validation and profiling of hit-to-lead compounds (drug candidates). This...

Read More